hepatitis c virus

Explore "hepatitis c virus" with insightful episodes like "Key Viral Hepatitis Studies Influencing My Practice Following AASLD 2021", "Tackling Racial Disparities in HCV Care: Global Edition", "Hepatitis C vaccine", "Hepatitis C vaccine" and "Viruses, how to be the perfect host" from podcasts like ""CCO Infectious Disease Podcast", "CCO Infectious Disease Podcast", "Translational Medicine", "Epidemics and Vaccines" and "Translational Medicine"" and more!

Episodes (6)

Key Viral Hepatitis Studies Influencing My Practice Following AASLD 2021

In this episode, Nancy Reau, MD, discusses new viral hepatitis data from AASLD 2021, including:

HBV treatment in pregnancy
Outcomes following HBV treatment withdrawal
Progress toward an HBV cure
HCV implementation science and current status of the cascade of care
Hepatitis delta virus: understanding the clinical impact
Phase III clinical trial updates for hepatitis delta virus, including data on bulevirtide

Presenter:

Nancy Reau, MD
Professor of Medicine
Chief, Section of Hepatology
Associate Director, Solid Organ Transplantation
Richard B. Capps Chair of Hepatology
Rush University Medical Center
Chicago, Illinois

Follow along with the downloadable slideset at:
https://bit.ly/3d6NQRV

Link to full program:
https://bit.ly/3lputrT

CCO Infectious Disease Podcast

enDecember 01, 2021

implementation science

Tackling Racial Disparities in HCV Care: Global Edition

In this episode, Prof Ashley Brown, BSc, MD, FRCP, and Ahmed M. Elsharkawy, PhD, FRCP(UK), discuss key racial inequities of care that lead to undertreatment for migrant populations and other racial minorities globally with or at risk for hepatitis C.

Topics include:

HCV Burden and Care Disparities in Specific Populations
Genotypes and Length of Infection in Ethnic Minorities
Primary Care Education and System-Related Barriers
Solutions to Overcome Barriers to HCV Care
First-hand Patient Stories

Prof Ashley Brown, BSc, MD, FRCP
Professor of Practice, Viral Hepatitis
Division of Metabolism, Digestion and Reproduction
Imperial College London
Consultant Hepatologist
Liver & Antiviral Unit
Imperial College Healthcare NHS Trust
London, United Kingdom

Ahmed M. Elsharkawy, PhD, FRCP(UK)
Consultant Hepatologist and
Honorary Senior Lecturer
Liver Unit and Biomedical Research Centre
University Hospitals Birmingham
University of Birmingham
Birmingham, United Kingdom

Content based on a CME program supported by educational grants provided by AbbVie; Gilead Sciences, Inc.; and Janssen Therapeutics, Division of Janssen Products, LP

To follow along, download the slides at:
https://bit.ly/36UDLVi

Link to full program:
https://bit.ly/3kKIb9a

CCO Infectious Disease Podcast

enNovember 17, 2021

Hepatitis C vaccine

Dr Ellie Barnes talks about her research on Hepatitis C and her work on a T cell vaccine. Dr Ellie Barnes aims to develop a prophylactic and a therapeutic hepatitis C virus vaccine to combat a global epidemic currently infecting 170 million people worldwide. Many chronically infected patients silently develop complications of liver disease that can include hepatocellular cancer, liver cirrhosis and liver failure.

Translational Medicine

enApril 03, 2012

Hepatitis C vaccine

Dr Ellie Barnes talks about her research on Hepatitis C and her work on a T cell vaccine. Hepatitis C virus is a global epidemic, affecting around 200 million people worldwide. Many chronically infected patients silently develop complications of liver disease that can include hepatocellular cancer, liver cirrhosis and liver failure. Unlike other vaccines, inducing antibody reactions to Hepatitis C is often ineffective because antibodies only target the outer surface of the virus. To combat this Dr Ellie Barnes is developing a new therapeutic vaccine for this damaging virus.

Epidemics and Vaccines

enApril 03, 2012

Viruses, how to be the perfect host

Professor Paul Klenerman talks about our relationship with persistent viruses, such as Hepatitis C. Prof. Paul Klenerman studies the evolutionary relationships between persistent viruses and their human hosts. He aims to understand the role of our immune responses in determining the outcome of Hepatitis C virus infection. Hepatitis C virus infects around 200 million people worldwide and is a major cause of liver disease.

Translational Medicine

enDecember 12, 2011

virus

hiv

liver and flow cytometry

hepatitis c virus

t cells

Viruses, how to be the perfect host

Professor Paul Klenerman talks about our relationship with persistent viruses, such as Hepatitis C. Hepatitis C virus infects around 200 million people worldwide and is a major cause of liver disease. Understanding immune responses to the virus could help to protect or cure people with Hepatitis C. Professor Paul Klenerman studies relationships between persistent viruses such as Hepatitis C and their human hosts. Professor Klenerman aims to understand the role of our immune responses in determining the outcome of Hepatitis C virus infection.

Epidemics and Vaccines

enDecember 12, 2011

virus

hiv

liver and flow cytometry

hepatitis c virus

t cells

On this page

hepatitis c virus

Episodes (6)

Key Viral Hepatitis Studies Influencing My Practice Following AASLD 2021

Tackling Racial Disparities in HCV Care: Global Edition

Hepatitis C vaccine

Hepatitis C vaccine

Viruses, how to be the perfect host

Viruses, how to be the perfect host